S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:BNTC

Benitec Biopharma (BNTC) Stock Price, News & Analysis

$5.25
+0.12 (+2.34%)
(As of 03/28/2024 ET)
Today's Range
$5.05
$5.27
50-Day Range
$2.80
$5.62
52-Week Range
$1.86
$9.01
Volume
20,970 shs
Average Volume
15,254 shs
Market Capitalization
$13.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Benitec Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
90.5% Upside
$10.00 Price Target
Short Interest
Healthy
0.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.39mentions of Benitec Biopharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.72 out of 5 stars

Medical Sector

451st out of 938 stocks

Pharmaceutical Preparations Industry

211th out of 425 stocks

BNTC stock logo

About Benitec Biopharma Stock (NASDAQ:BNTC)

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

BNTC Stock Price History

BNTC Stock News Headlines

11 Best ASX Stocks To Buy Now
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Benitec Biopharma Inc BNTC
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
JMP Securities Sticks to Its Buy Rating for Benitec Biopharma (BNTC)
Benitec Biopharma Inc.
Benitec Biopharma Shares Double on FDA Clearance
See More Headlines
Receive BNTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BNTC
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+94.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-19,560,000.00
Pretax Margin
-35,754.10%

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
$0.12 per share

Miscellaneous

Free Float
2,481,000
Market Cap
$13.29 million
Optionable
No Data
Beta
1.02
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Jerel A. Banks M.D. (Age 49)
    Ph.D., Executive Chairman & CEO
    Comp: $848.07k
  • Ms. Megan Joan Boston BComm (Age 52)
    CA, Dip., GAICD, Executive Director
    Comp: $439.17k
  • Dr. Michael Graham
    Head of Discovery & Founding Scientist
  • Dr. Claudia Kloth
    Senior Vice President of Manufacturing

BNTC Stock Analysis - Frequently Asked Questions

Should I buy or sell Benitec Biopharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BNTC shares.
View BNTC analyst ratings
or view top-rated stocks.

What is Benitec Biopharma's stock price target for 2024?

1 analysts have issued 12-month price targets for Benitec Biopharma's stock. Their BNTC share price targets range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 90.5% from the stock's current price.
View analysts price targets for BNTC
or view top-rated stocks among Wall Street analysts.

How have BNTC shares performed in 2024?

Benitec Biopharma's stock was trading at $3.23 on January 1st, 2024. Since then, BNTC shares have increased by 62.5% and is now trading at $5.25.
View the best growth stocks for 2024 here
.

Are investors shorting Benitec Biopharma?

Benitec Biopharma saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 5,100 shares, a drop of 68.3% from the February 29th total of 16,100 shares. Based on an average daily trading volume, of 14,500 shares, the short-interest ratio is currently 0.4 days. Currently, 0.2% of the company's shares are short sold.
View Benitec Biopharma's Short Interest
.

When is Benitec Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our BNTC earnings forecast
.

How were Benitec Biopharma's earnings last quarter?

Benitec Biopharma Inc. (NASDAQ:BNTC) issued its quarterly earnings data on Tuesday, February, 13th. The biotechnology company reported ($2.64) earnings per share for the quarter.

When did Benitec Biopharma's stock split?

Shares of Benitec Biopharma reverse split on the morning of Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Benitec Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), BioLineRx (BLRX) and CRISPR Therapeutics (CRSP).

When did Benitec Biopharma IPO?

Benitec Biopharma (BNTC) raised $0 in an initial public offering on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager.

Who are Benitec Biopharma's major shareholders?

Benitec Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.64%), Vanguard Group Inc. (0.65%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Benitec Biopharma?

Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BNTC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners